Date:June 14, 2012

Jack Su, MD

Jack Su, M.D.Assistant Professor
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine

Hyundai Pediatric Cancer Research Scholar

Dr. Jack Su
6701 Fannin Street, Suite 1510
Houston, TX 77030

Phone: 832-822-4306
Fax: 832-825-1503


Dr. Jack Su’s research interest is in translational oncology and developing novel agents for treating pediatric CNS tumors. Dr. Su conducted a Children’s Oncology Group phase I study of valproic acid in children with recurrent solid tumors, including brain tumors. He is also developing clinical trials of additional histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), and a poly(ADP-ribose) polymerase (PARP) inhibitor for pediatric CNS tumors. In collaboration with Drs. Xiao-Nan Li, Susan Blaney, and Ching Lau, Dr. Su is conducting pre-clinical studies of HDAC inhibitors, PARP inhibitors, and DNA methylation inhibitors for future clinical trials in pediatric CNS tumors.

Dr. Jack Su is a member of the Brain Tumor Program.


M.D. and Residency, University of California, San Francisco
Fellowship, Baylor College of Medicine

Board Certifications

American Board of Pediatrics
American Board of Pediatrics-Hematology/Oncology

Selected Memberships

Study Chair, ADVL0419, Phase I Study of Valproic Acid in Children with Recurrent/Progressive Solid Tumors Including CNS Tumors, Children’s Oncology Group (COG)
Member, Pediatric Brain Tumor Consortium (PBTC)
Member, Society of Neuro-Oncology
Member, American Association of Cancer Research (AACR)

Clinical Special Interests


Research Interests

Translational oncology
Developing novel agents for treating pediatric CNS tumors